Cell-Specific Inhibition of p38α as a Therapeutic Strategy for Inflammatory Bowel Disease by McNamee, Eóin N. et al.
C
I
A
m
p
i
m
m
a
n
a
p
s
u
I
v
f
i
p
a
c
r
a
h
s
e
a
(
(
w
t
T
t
t
h
m
a
a
s
d
Editorialsell-Specific Inhibition of p38 as a Therapeutic Strategy for
nflammatory Bowel Diseaset
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See “Distinct effects of p38 deletion in myeloid
lineage and gut epithelia in mouse models of
inflammatory bowel disease,” by Otsuka M,
Kang YJ, Ren J, et al, on page 1255.
nti-tumor necrosis factor (TNF) therapies have pro-
vided an invaluable therapeutic alternative to im-
unomodulators, corticosteroids, and mesalamine com-
ounds for the induction and maintenance of remission in
nflammatory bowel disease (IBD). However, sustained re-
ission drops significantly at 1 year, and the efficacy of
anipulating other cytokines (eg, interleukin [IL]-6, IL-10,
nd IL-11) has been limited.1–3 Therefore, there is an unmet
eed for alternative biological therapies. Restoring the bal-
nce of pro- and anti-inflammatory pathways in IBD is a
otential strategy that deserves further examination. A pro-
pective novel approach is to target molecular pathways
pstream of the proinflammatory cytokines that mediate
BD, such as nuclear factor (NF)-B and the mitogen acti-
ated protein kinases (MAPKs). MAPKs comprise a large
amily of highly conserved serine/threonine protein kinases
mplicated in the regulation of a vast array of key cellular
rocesses, such as production of cytokines, migration and
ccumulation of leukocytes, and angiogenesis, all of which
ontribute to the pathogenesis of IBD. Because of their key
egulatory role in the production of inflammatory cytokines
nd in mediating their downstream effects, their inhibition
as received considerable attention as a novel therapeutic
trategy for inflammatory diseases.
In mammals, there are 3 major classes of MAPKs, the
xtracellular signal-regulated kinases and the 2 stress-
ctivated protein kinase families, c-jun N-terminal kinase
JNK) and p38. The p38 family is composed of 4 isoforms
, , , and ). The , , and  isoforms are expressed
idely in leukocyte subsets including CD4 T cells, neu-
rophils, monocytes, macrophages, and endothelial cells.4
he p38 isoform has received the most attention as a
herapeutic target owing to its critical role in the post-
ranscriptional regulation of inflammatory genes.4,5 In-
ibitors of p38 have been shown to block proinflam-
atory cytokines such as interferon-, TNF, IL-1, IL-8,
nd cyclooxygenase-2 production from myeloid cells, in
ddition to reducing mortality from endotoxin-induced
hock and inhibiting the development of collagen-in-
uced arthritis in animal models.5–7 Furthermore, activa- sion of p38 stabilizes the 3=-untranslated region of
RNA from rapidly turned over inflammatory cytokines
uch as TNF and IL-1, via adenosine-uridine–rich ele-
ents. As such, p38 seems to be critical to the regula-
ion of proinflammatory cytokine synthesis, both at the
ranscriptional and translational levels.8
In human IBD, numerous studies have described in-
reased p38 phosphorylation, corresponding with increased
ytokine expression and leukocytic infiltration. Further-
ore, in patients with ulcerative colitis and Crohn’s disease,
38 expression was localized within invading macro-
hages and neutrophils near the intestinal epithelium.9,10
lthough a major emphasis has been placed on the role of
38 in the regulation of inflammatory cytokines, a criti-
ally important observation pertaining to IBD is that the
NF-dependent expression of mucosal addressin cell adhesion
olecule-1 (MAdCAM-1) is linked to p38. MAdCAM-1
rchestrates lymphocyte homing to both Peyer’s patches
nd gastrointestinal-associated lymphoid tissues and plays a
ole in the pathogenesis of IBD.11,12
The first synthetic p38 inhibitors, the pyridinyl imida-
oles (eg, SB203580 and SB202190), showed promising
nti-inflammatory results in vitro and in vivo, in models
f arthritis,13 chronic obstructive pulmonary disease, and
ome models of IBD.14 Moreover, there is now a large
rsenal of new p38 inhibitors (including triazanaptha-
enones, diaryl ureas, benzophenones, pyrazole ketones,
ndole amides, diamides, quinazolinones, pyrimido-pyri-
idinones),13,15 displaying efficacy in several preclinical
BD models, whereas others are currently undergoing
linical trials.16 However, many of these studies have
ncountered less than satisfactory efficacy or undesired
ide effects. One of the limitations of current p38 inhib-
tors stems from their competitive inhibition of the aden-
sine triphosphate binding pocket, resulting in drugs
ith excellent potency but insufficient specificity. This
ack of specificity resulted in the withdrawal of candidate
olecules from clinical trials, owing to unexpected side
ffects such as unexplained transaminase elevation.17 It
ay also explain the results of the most successful clin-
cal trial of a p38 inhibitor in Crohn’s disease (ie, CNI-
493), in which 50% of patients were in remission after 4
onths, yet further analyses revealed no decreased phos-
horylation of p38 in colonic biopsies. Thus, its clinical
ffect was attributed to JNK inhibition rather than to
ltered p38 activity.10 Although attempts to improve the
electivity and pharmacodynamics of p38 inhibitors con-
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Editorials continued
1
inue, this strategy remains mostly as a disappointing
ootnote in the search for novel IBD therapies.
Contrary to the conflicting results of broad spectrum p38
nhibitors, the cell-specific deletion of p38 has previously
hown marked anti-inflammatory effects. Targeted deletion
f p38 in macrophages impaired the response to the Toll-
ike receptor-4 ligand lipopolysaccharide (LPS) with reduced
NF, IL-12, and IL-18, in addition to reduced activation of
ranscription factors C/EBP- and CREB in LPS-treated
38-deficient macrophages. Furthermore, after in vivo
hallenge with LPS, p38 conditional knockout mice
howed significantly lower TNF levels in sera and prolonged
urvival times.18 The selective transgenic inhibition of p38
n macrophages was also protective in mice, in both acute
nd chronic models of cutaneous inflammation.19 Further
ecent findings have elaborated on the use of cell-specific
herapies in preclinical models of IBD. Delivery of anti-sense
ligonucleotides targeting TNF into infiltrating colonic
acrophages markedly protected mice from CD45RBhigh
igure 1. Effect of selective epithelial or myeloid p38 inhibition on int
balance between proliferation and differentiation of epithelial precurso
oblets cells have a protective role in maintaining barrier function. (B) Inh
ell differentiation culminating in barrier breakdown and tissue injury. (C)nflammatory signaling, production of proinflammatory cytokines and marked
238nd trinitrobenzene sulfonic acid–induced colitis.20 These
elective inhibition studies highlight the possibility of tar-
eted cellular therapies for chronic inflammatory diseases,
erhaps with lessened interference with physiologic im-
une responses, which is a significant concern with current
biologic” therapies.
In this issue of GASTROENTEROLOGY, Otsuka et al21 have
legantly identified a dichotomy between the actions of p38
n mucosal epithelial cells and those of the infiltrating
yeloid lineage, which may shed new light on the current
ailings of broad-spectrum p38 inhibitors in IBD (Figure 1).
he authors demonstrate that, although the use of p38/
nhibition with the antagonist SB203580 had no significant
eneficial effects on clinical indices, selective deletion of
38 in myeloid cells had a protective effect in colitis
nduced by acute dextran sulphate sodium treatment. This
rotection was mediated in part by the reduced activation
f the MAPK-responsive transcription factors AP-1, GAS,
nd NF-B. As has been reported previously through p38
l homeostasis. (A) Intestinal homeostasis requires the maintenance of
d the regulation of physiologic leukocyte recruitment. Mucus-secreting
of P38 in epithelial cells leads to hyper proliferation and lack of goblet
ersely, specific P38 inhibition in the myeloid lineage results in reducedestina
rs an
ibition
Convprotection from colitis.
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Editorials continuednhibition of macrophages, the expression of the colonic
roinflammatory cytokines IL-1, IL-6, IL-12p40, and TNF
as reduced.18 The authors also emphasized the critical role
or p38 during physiologic epithelial cell homeostasis.
reatment of mice with the p38/ antagonist, SB203580,
nd epithelial-specific p38-deletion inhibited the homeo-
tatic control of epithelial cell differentiation and prolifer-
tion and resulted in a decreased production of goblet cells.
ecause the levels of mucus secreted by goblet cells have a
rotective role in the intestine,22 broad-spectrum p38/
nhibition may predispose the intestine to epithelial dam-
ge, bacterial invasion, and dysregulated immune responses
Figure 1).
Clearly, MAPKs play important roles in transducing
nflammatory signals and therefore are key molecular
argets for therapeutic intervention in chronic inflamma-
ory diseases such as IBD. However, because multiple
soforms of these kinases are implicated in the regulation
f essential cellular responses, broad-spectrum MAPK
nhibition is likely to result in serious side effects. By
ontrast, cell-specific p38 inhibition or small molecular
nhibitors of the downstream, inflammation-restricted
APK signaling of infiltrating pathogenic leukocytes
uring chronic inflammation is a potential novel thera-
eutic strategy that may further the physician’s arma-
entarium for the treatment of IBD in the near future.
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